October 19, 2023
Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis
NM26 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets,
targeting the underlying inflammation as well as the neuroinflammatory pathway that causes itch